NCT02401815View on ClinicalTrials.gov

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 6, 2015

Primary Completion Date

May 11, 2020

Study Completion Date

May 11, 2020

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

CGT9486

CGT9486 will be administered per dose and schedule specified in the arm.

DRUG

Pexidartinib

Pexidartinib capsules will be administered per dose and schedule specified in the arm.

DRUG

Sunitinib

Sunitinib will be administered per dose and schedule specified in the arm.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

33136

Sylvester Comprehensive Cancer Center/ UMHC, Miami

43210

OSU Comprehensive Cancer Center, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Plexxikon
All Listed Sponsors
collaborator

Plexxikon

INDUSTRY

lead

Cogent Biosciences, Inc.

INDUSTRY